Cleveland Biolabs Inc. Announces New Patents Strengthening Entolimod Portfolio

BUFFALO, NY--(Marketwired - August 18, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance or issuance of several new patents for entolimod in the U.S. and other countries, further bolstering its patent position.

Cleveland BioLabs, Inc. recently secured an additional composition of matter patent in the U.S. in the patent family that covers the Company’s lead agent, the flagellin-derived entolimod, as well as various other flagellin-derived agents, for any use, including the biodefense and medical indications that CBLI is pursuing.

Cleveland BioLabs now has more than 10 issued or allowed U.S. patents covering compositions of matter and methods of use claims relating to entolimod’s biodefense indication, as well as chemo- and radiation therapy adjuvant and reperfusion injury indications. Additional pending U.S. patent claims include those covering oncology and other biodefense methods of use.

Patents covering methods of protecting against radiation using flagellin/entolimod were also recently allowed or granted in Israel, Singapore, and Hong Kong, bringing the number of issued global patents covering composition of matter and uses of entolimod to over 50. Numerous additional entolimod patent applications are pending worldwide.

Yakov Kogan, Ph.D., Chief Executive Officer of Cleveland BioLabs, commented, “These new patents further expand our intellectual property position around entolimod. We believe that our strong patent portfolio is an important competitive advantage and key to the success of our future commercialization of entolimod’s biodefense indication in the U.S. and abroad.”

About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company’s proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company’s most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company’s website at http://www.cbiolabs.com.

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words and phrases such as “pending,” “believe,” “positions us,” “future,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to successfully submit and receive approval of our pre-EUA application for entolimod, the conduct and results of our various clinical trials; our ability to obtain approval from the U.S. Food and Drug Administration of our product candidates; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

These risks and uncertainties include, among others, our ability to obtain, maintain and protect intellectual property rights (including for entolimod and other pipeline candidates); the Company’s failure to successfully and timely develop existing and new products; the Company’s collaborative relationships and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company’s ability to comply with its obligations under license agreements; the Company’s inability to obtain regulatory approval in a timely manner or at all; subsequent changes in the agreement with the Russian Ministry of Industry and Trade; and the Company’s history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the “Risk Factors” and “Forward-Looking Statements” described in the Company’s periodic filings with the Securities and Exchange Commission.